Interobserver variability in the evaluation of mismatch repair protein immunostaining.

[1]  S. Gruber,et al.  Microsatellite instability in colorectal cancer—the stable evidence , 2010, Nature Reviews Clinical Oncology.

[2]  Laura H. Tang,et al.  Immunohistochemistry as First-line Screening for Detecting Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome: A 2-antibody Panel May be as Predictive as a 4-antibody Panel , 2009, The American journal of surgical pathology.

[3]  C. Compton,et al.  Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Heather Hampel,et al.  Feasibility of screening for Lynch syndrome among patients with colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Ligtenberg,et al.  Interpretation of Immunohistochemistry for Mismatch Repair Proteins is Only Reliable in a Specialized Setting , 2008, The American journal of surgical pathology.

[6]  J. Shia.  Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. , 2008, The Journal of molecular diagnostics : JMD.

[7]  John D Potter,et al.  Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. , 2007, Gastroenterology.

[8]  P. Propping,et al.  Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining , 2005, The Journal of pathology.

[9]  W. Gerald,et al.  Value of Immunohistochemical Detection of DNA Mismatch Repair Proteins in Predicting Germline Mutation in Hereditary Colorectal Neoplasms , 2005, The American journal of surgical pathology.

[10]  J. Rüschoff,et al.  Challenges and pitfalls in HNPCC screening by microsatellite analysis and immunohistochemistry. , 2004, The Journal of molecular diagnostics : JMD.

[11]  D. Klimstra,et al.  The utility of immunohistochemical detection of DNA mismatch repair gene proteins , 2004, Virchows Archiv.

[12]  J. Jass,et al.  Diagnosis of hereditary non-polyposis colorectal cancer (HNPCC). , 2004, Gut.

[13]  A. Lindblom,et al.  Microsatellite instability analysis and/or immunostaining for the diagnosis of hereditary nonpolyposis colorectal cancer? , 2004, Virchows Archiv.

[14]  H. Schackert,et al.  Involvement of hMSH6 in the development of hereditary and sporadic colorectal cancer revealed by immunostaining is based on germline mutations, but rarely on somatic inactivation , 2002, International journal of cancer.

[15]  T. Ørntoft,et al.  The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) – Results of an international collaborative study , 2001, Familial Cancer.

[16]  J. Jass,et al.  Origins of ... familial cancer: histopathological perspectives. , 1997, Journal of clinical pathology.

[17]  W. Grove,et al.  A latent trait finite mixture model for the analysis of rating agreement. , 1993, Biometrics.

[18]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[19]  D. Chang,et al.  The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch Syndrome: from bench to bedside , 2007, Familial Cancer.

[20]  M. Kloor,et al.  Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer , 2006, International journal of cancer.

[21]  C. Boland,et al.  Evolution of the Nomenclature for the Hereditary Colorectal Cancer Syndromes , 2004, Familial Cancer.